Eight of nine evaluable patients with AL amyloidosis with cardiac involvement either achieved responses or were considered stable DUBLIN, Ireland, April 23, 2014 -- Prothena Corporation plc , a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases ... (more)
http://ift.tt/1noX3WR
http://ift.tt/1noX3WR
No comments:
Post a Comment